Durgical
EN
Open the app

Newly diagnosed cancer: the clinical approach

  • Topic

A new cancer raises four questions, in order: what is it, how far has it spread, how fit is the patient and what is the goal? Answer them before treating.

Updated

What it is

The structured first steps after a cancer is suspected: confirm it on tissue (type, grade and markers), stage it with the tests that suit that tumour, measure the patient's fitness (performance status, comorbidities, organ function, wishes), agree the intent of treatment in a multidisciplinary tumour board, and then measure the response with standard criteria such as RECIST.

Key facts

  • Biopsy choice: the least invasive route that gives enough tissue for histology, immunohistochemistry and molecular tests; for a suspected metastasis, the most accessible lesion that would also prove the stage.
  • Molecular markers now decide treatment in many cancers (hormone receptors and HER2 in breast; EGFR, ALK and PD-L1 in lung), so the sample must be large enough.
  • Karnofsky runs from 100 (normal, no complaints) down in steps of 10 to 0 (dead); 70 means self-care but no normal work, 50 considerable help and frequent medical care, 30 severely disabled.
  • ECOG 0–1 roughly matches Karnofsky 70–100; most trials and many intensive treatments require ECOG 0–2.
  • Neoadjuvant treatment is given before the main (usually surgical) treatment, adjuvant after it to kill residual microscopic disease.
  • RECIST stable disease means neither enough shrinkage for a partial response nor enough growth for progression; complete response is disappearance of all target lesions.

Step by step

  1. Suspicion: symptoms, screening or an incidental finding; in Colombia, suspected cancer is prioritised for diagnostic tests by law.
  2. Tissue: biopsy, histological type, grade, immunohistochemistry and molecular markers.
  3. Staging work-up chosen for that tumour (examination, imaging, markers) gives the clinical stage (cTNM).
  4. Patient assessment: performance status (ECOG or Karnofsky), comorbidities, organ function, nutrition, social situation and the patient's goals.
  5. Tumour board: surgery, oncology, radiotherapy, pathology and radiology agree the intent and the plan.
  6. The plan is explained and agreed with the patient and family, with palliative care involved from the start.
  7. Treatment, then response assessment at set intervals with RECIST (or the criteria for that disease) to continue, change or stop.

Performance status: what each level means

ECOGWhat the patient can doApproximate KarnofskyUsual implication
0Fully active, no restrictions90–100Fit for most treatments and trials
1Restricted in strenuous activity; walks, light or desk work70–80Fit for most treatments and trials
2Walks and self-cares, cannot work; up more than half the day50–60Selected treatments; intensive regimens and many trials less suitable
3Limited self-care; in bed or chair more than half the day30–40Intensive treatment usually harms more than it helps, unless the cancer causes the decline and is very treatable
4Completely disabled, bed-bound, no self-care10–20Comfort-focused care, same exception
5Dead0—

Clinical notes

  • Ask first whether a tissue diagnosis is possible and safe; a carcinoma of unknown primary still needs tissue to guide treatment.
  • Write the intent in the notes and say it plainly to the patient: «we aim to cure», «we aim to control it and give you more time» or «we aim to keep you comfortable».
  • Reassess performance status at every visit: a fall from ECOG 1 to 3 changes what is reasonable.
  • Lymphomas use Lugano criteria with PET-CT, not RECIST; immunotherapy can cause pseudoprogression, so early growth is confirmed on a repeat scan (iRECIST).
  • In Colombia, Ley 1384 de 2010 sets up functional cancer care units with a multidisciplinary team, a tumour committee and a palliative care programme from the start of treatment.

Common traps

  • A mass on CT with a raised tumour marker is enough to start treatment: a biopsy is needed in almost every case, because type, grade and molecular targets decide the treatment
  • Poor performance status always rules out treatment: if the cancer itself causes the decline and is very sensitive (lymphoma, germ-cell tumour, small-cell lung cancer), treatment can restore function
  • Palliative intent means no active treatment: palliative chemotherapy, radiotherapy and surgery are active treatments for symptoms and time, and palliative care runs alongside from diagnosis
  • Target lesions shrinking means response even if a new lesion appears: under RECIST an unequivocal new lesion is progressive disease
  • The tumour board decides and the patient is informed: the board recommends; the patient's goals and consent turn the recommendation into a plan

Test yourself

Think of the answer, then tap the question to see it.

A 58-year-old woman has a lung mass, liver lesions and a raised CEA. What is the next step before any cancer treatment, and why?

A biopsy, preferably of the most accessible lesion that would also confirm the stage (a liver lesion). Type and molecular markers decide treatment; a scan and a marker cannot.

What does ECOG 2 mean, and how does it differ from ECOG 3?

ECOG 2: walks and cares for self but cannot work, up more than half the waking day. ECOG 3: limited self-care, in bed or chair more than half the day.

How do curative, life-prolonging and palliative intent change how much toxicity is acceptable?

Curative: more toxicity is accepted for the chance of cure. Life-prolonging: benefit and harm are balanced. Palliative: treatment must relieve symptoms or improve quality of life with little burden.

Under RECIST, the sum of target lesions falls by 40% but a new liver lesion appears. What is the response?

Progressive disease: any unequivocal new lesion means progression, whatever the target lesions do.

Why is a performance status of ECOG 3 not an absolute bar to treatment in a young man with newly diagnosed lymphoma?

His decline is caused by a highly treatment-sensitive cancer; treating it can restore function, so the poor status reflects the disease rather than fixed frailty.

Add to my cards (5)

More Pathology questions →

Elsewhere in DurgiPedia

Connections

← All of general pathology

Educational content on the mechanisms of disease; not a diagnostic or treatment guide and no substitute for a health professional's advice. No doses are given.

Sources: Tests and Procedures Used to Diagnose Cancer (National Cancer Institute (NCI), 2026); ECOG Performance Status Scale (ECOG-ACRIN Cancer Research Group, 2026); Benefits and Limitations of a Multidisciplinary Approach in Cancer Patient Management (Cancer Management and Research (Dove Medical Press), 2020); Assessing the reliability of Response Evaluation Criteria In Solid Tumors (RECIST): a systematic review of the factors contributing to inter-observer variability (Insights into Imaging, PubMed Central, 2026); Ley 1384 de 2010 (Ley Sandra Ceballos), por la cual se establecen las acciones para la atención integral del cáncer en Colombia (Congreso de Colombia (Normograma INVIMA), 2010).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.